Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi ...
Early numbers say the mechanism underlying the search for viable molecules is real Read more at The Business Times.
Koray Kavukcuoglu, DeepMind's chief technology officer and Google's chief AI architect, is taking on the operational ...
A quartet of top AI figures at Google DeepMind have to form their own startup – Discovery Loop – dedicated to speeding up research across life sciences and other industries.
Management lowered 2026 full-year cash operating expense guidance to $375 million, representing a nearly 40% reduction from 2024 pro forma expenses through improved ROI on technology. Additional Phase ...
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...
Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: Bank ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation Committee of Recursion's Board of ...
A language takes work off your hands, gives it to a compiler, runtime, or toolchain, and charges you somewhere else.
Scientific research publishing is a particularly lucrative industry. The most recent estimates suggest that it generates around 19 billion US dollars (or 16.67 billion euros) in annual turnover, with ...
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results